Literature DB >> 21195387

Neuroanatomic predictors to prodromal psychosis in velocardiofacial syndrome (22q11.2 deletion syndrome): a longitudinal study.

Wendy R Kates1, Kevin M Antshel, Stephen V Faraone, Wanda P Fremont, Anne Marie Higgins, Robert J Shprintzen, Jo-Anna Botti, Lauren Kelchner, Christopher McCarthy.   

Abstract

BACKGROUND: Up to 30% of young adults with velocardiofacial syndrome (VCFS; 22q11.2 deletion syndrome) develop schizophrenia or psychosis. Identifying the neuroanatomic trajectories that increase risk for psychosis in youth with this genetic disorder is of great interest.
METHODS: We acquired high-resolution anatomic magnetic resonance images and measures of psychiatric function on 72 youth with VCFS, 26 unaffected siblings, and 24 age-matched community control subjects at two time points: between late childhood (mean age 11.9 years) and mid-adolescence (mean age 15.1 years).
RESULTS: With the exception of cranial gray matter and orbitofrontal prefrontal cortex, neuroanatomic trajectories in youth with VCFS were comparable to unaffected siblings and community control subjects during this developmental window. However, in youth with VCFS, longitudinal decreases in the volumes of cranial gray and white matter, prefrontal cortex, mesial temporal lobe, and cerebellum were associated with increased combined prodromal symptoms at Time 2. In contrast, only decreases in temporal lobe gray matter volumes (p < .002) and verbal IQ (p < .002) predicted specifically to positive prodromal symptoms of psychosis at Time 2.
CONCLUSIONS: These findings are in line with studies of non-VCFS individuals at risk for schizophrenia and suggest that early decrements in temporal lobe gray matter may be predictive of increased risk of prodromal psychotic symptoms in youth with VCFS.
Copyright © 2011 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21195387      PMCID: PMC3081962          DOI: 10.1016/j.biopsych.2010.10.027

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  60 in total

1.  Brain development during childhood and adolescence: a longitudinal MRI study.

Authors:  J N Giedd; J Blumenthal; N O Jeffries; F X Castellanos; H Liu; A Zijdenbos; T Paus; A C Evans; J L Rapoport
Journal:  Nat Neurosci       Date:  1999-10       Impact factor: 24.884

2.  Indices of discrimination or diagnostic accuracy: their ROCs and implied models.

Authors:  J A Swets
Journal:  Psychol Bull       Date:  1986-01       Impact factor: 17.737

Review 3.  Form of empirical ROCs in discrimination and diagnostic tasks: implications for theory and measurement of performance.

Authors:  J A Swets
Journal:  Psychol Bull       Date:  1986-03       Impact factor: 17.737

4.  Brain and behaviour in children with 22q11.2 deletion syndrome: a volumetric and voxel-based morphometry MRI study.

Authors:  Linda E Campbell; Eileen Daly; Fiona Toal; Angela Stevens; Rayna Azuma; Marco Catani; Virginia Ng; Therese van Amelsvoort; Xavier Chitnis; William Cutter; Declan G M Murphy; Kieran C Murphy
Journal:  Brain       Date:  2006-03-28       Impact factor: 13.501

Review 5.  Deletions of human chromosome 22 and associated birth defects.

Authors:  P J Scambler
Journal:  Curr Opin Genet Dev       Date:  1993-06       Impact factor: 5.578

6.  Automated Talairach atlas-based parcellation and measurement of cerebral lobes in children.

Authors:  W R Kates; I S Warsofsky; A Patwardhan; M T Abrams; A M Liu; S Naidu; W E Kaufmann; A L Reiss
Journal:  Psychiatry Res       Date:  1999-07-30       Impact factor: 3.222

7.  Hippocampal and ventricular volumes in psychotic and nonpsychotic bipolar patients compared with schizophrenia patients and community control subjects: a pilot study.

Authors:  Heather C Strasser; Jessica Lilyestrom; Ebony R Ashby; Nancy A Honeycutt; David J Schretlen; Ann E Pulver; Ramona O Hopkins; J Raymond Depaulo; James B Potash; Barbara Schweizer; Khara O Yates; Elizabeth Kurian; Patrick E Barta; Godfrey D Pearlson
Journal:  Biol Psychiatry       Date:  2005-03-15       Impact factor: 13.382

8.  Amygdala volume correlates positively with fearfulness in normal healthy girls.

Authors:  Ellen A A van der Plas; Aaron D Boes; John A Wemmie; Daniel Tranel; Peg Nopoulos
Journal:  Soc Cogn Affect Neurosci       Date:  2010-02-11       Impact factor: 3.436

9.  Magnetic resonance imaging of brain in people at high risk of developing schizophrenia.

Authors:  S M Lawrie; H Whalley; J N Kestelman; S S Abukmeil; M Byrne; A Hodges; J E Rimmington; J J Best; D G Owens; E C Johnstone
Journal:  Lancet       Date:  1999-01-02       Impact factor: 79.321

10.  Progressive brain structural changes mapped as psychosis develops in 'at risk' individuals.

Authors:  Daqiang Sun; Lisa Phillips; Dennis Velakoulis; Alison Yung; Patrick D McGorry; Stephen J Wood; Theo G M van Erp; Paul M Thompson; Arthur W Toga; Tyrone D Cannon; Christos Pantelis
Journal:  Schizophr Res       Date:  2009-01-12       Impact factor: 4.939

View more
  42 in total

1.  Clinical and genetic high-risk paradigms: converging paths to psychosis meet in the temporal lobes.

Authors:  Maria Jalbrzikowski; Carrie E Bearden
Journal:  Biol Psychiatry       Date:  2011-05-15       Impact factor: 13.382

Review 2.  The 22q11.2 deletion syndrome as a window into complex neuropsychiatric disorders over the lifespan.

Authors:  Rachel K Jonas; Caroline A Montojo; Carrie E Bearden
Journal:  Biol Psychiatry       Date:  2013-08-28       Impact factor: 13.382

3.  Abnormalities in white matter tracts in the fronto-striatal-thalamic circuit are associated with verbal performance in 22q11.2DS.

Authors:  Carina Heller; Saskia Steinmann; James J Levitt; Nikos Makris; Kevin M Antshel; Wanda Fremont; Ioana L Coman; Stefan R Schweinberger; Thomas Weiß; Sylvain Bouix; Marek R Kubicki; Wendy R Kates; Zora Kikinis
Journal:  Schizophr Res       Date:  2020-10-23       Impact factor: 4.939

4.  White matter microstructural abnormalities of the cingulum bundle in youths with 22q11.2 deletion syndrome: associations with medication, neuropsychological function, and prodromal symptoms of psychosis.

Authors:  Wendy R Kates; Amy K Olszewski; Matthew H Gnirke; Zora Kikinis; Joshua Nelson; Kevin M Antshel; Wanda Fremont; Petya D Radoeva; Frank A Middleton; Martha E Shenton; Ioana L Coman
Journal:  Schizophr Res       Date:  2014-07-25       Impact factor: 4.939

5.  Cortical gyrification in velo-cardio-facial (22q11.2 deletion) syndrome: a longitudinal study.

Authors:  Arun Kunwar; Seethalakshmi Ramanathan; Joshua Nelson; Kevin M Antshel; Wanda Fremont; Anne Marie Higgins; Robert J Shprintzen; Wendy R Kates
Journal:  Schizophr Res       Date:  2012-02-22       Impact factor: 4.939

6.  White matter abnormalities in 22q11.2 deletion syndrome: preliminary associations with the Nogo-66 receptor gene and symptoms of psychosis.

Authors:  Matthew D Perlstein; Moeed R Chohan; Ioana L Coman; Kevin M Antshel; Wanda P Fremont; Matthew H Gnirke; Zora Kikinis; Frank A Middleton; Petya D Radoeva; Martha E Shenton; Wendy R Kates
Journal:  Schizophr Res       Date:  2013-12-08       Impact factor: 4.939

Review 7.  Converging levels of analysis on a genomic hotspot for psychosis: insights from 22q11.2 deletion syndrome.

Authors:  Matthew J Schreiner; Maria T Lazaro; Maria Jalbrzikowski; Carrie E Bearden
Journal:  Neuropharmacology       Date:  2012-10-23       Impact factor: 5.250

8.  Altered cognitive development in the siblings of individuals with schizophrenia.

Authors:  Deanna M Barch; Rachel Cohen; John Csernansky
Journal:  Clin Psychol Sci       Date:  2014-03-01

9.  Abnormal Auditory Processing and Underlying Structural Changes in 22q11.2 Deletion Syndrome.

Authors:  Lucia-Manuela Cantonas; Valentina Mancini; Tonia A Rihs; Vincent Rochas; Maude Schneider; Stephan Eliez; Christoph M Michel
Journal:  Schizophr Bull       Date:  2021-01-23       Impact factor: 9.306

10.  Secondary psychoses: an update.

Authors:  Matcheri S Keshavan; Yoshio Kaneko
Journal:  World Psychiatry       Date:  2013-02       Impact factor: 49.548

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.